Thursday, January 22, 2015


Why It's Time to Stop Hating Big Banks

Profits in finance are back with "Banking 2.0." My top financial pick for 2015 never took a bailout and made money throughout the Great Recession. Three times cited as the "Best Bank in the World," they offer investors a 21% upside this year, plus a 9.7% yield. Even better, you can buy this stock for less than $9 a share. It's hands down one of the best investments anywhere in the world. Curious?

Click here.

Happy Pills

Thomas Scarlett

You'd be hard pressed to find a drug company with stronger growth prospects than Gilead Sciences (NYSE: GILD). The firm's anti-hepatitis C drug, Sovaldi, is leading the market, and Gilead has several other promising products in the pipeline.

Gilead's stock price endured a rocky period late last year, due mostly to one disappointing earnings report and some concerns about the validity of Sovaldi's patents in other countries. But the upswing has already begun, and there is still room on the upside.

Gilead shares rebounded recently after the company announced it has signed an exclusive distribution deal with CVS Health (NYSE: CVS) for its two hepatitis C drugs, Sovaldi and Harvoni. According to the deal, the nation's second largest pharmacy benefit management business will not carry any competing drugs.

A full treatment of Sovaldi and Harvoni retails at a hefty $84,000 and $94,500, respectively and has irked some insurance companies and online distributor Express Scripts (NSDQ: ESRX). A few weeks ago, a viable hepatitis C contender appeared in the form of AbbVie's Veikira Pak and ESRX announced that it would drop Gilead from its offerings.

At $83,319 for a full treatment cycle, Veikira Pak isn't that much less than Gilead's drugs but AbbVie is only charging Express Scripts half of its retail price. CVS and Gilead have not said if a similar discount was agreed on.

Why is Sovaldi so successful for Gilead? First, it can cure Hepatitis C, as opposed to merely managing it. The success rate runs 80% to 90%, with few side effects, according to various reports. Second, Sovaldi costs $84,000 for the standard 12-week regimen.

Gilead now expects total-company 2015 sales of $23 billion to $24 billion. The current analyst consensus is for EPS of $7.54 this year. Gilead shares trade at less than 13 times the 2014 number. We think more share gains lie ahead, even after the strong advance seen in "Still Undervalued."

The company got some good news in October when the U.S. Food and Drug Administration(FDA) approved Harvoni (ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single tablet regimen for the treatment of chronic hepatitis C genotype 1 infection in adults.

Harvoni combines the NS5A inhibitor ledipasvir with the nucleotide analog polymerase inhibitor sofosbuvir, approved under the tradename SovaldiinDecember 2013. Harvoni's efficacy has been established in patients with chronic hepatitis C virus (HCV) genotype 1 infection, with a treatment duration of eight, 12 or 24 weeks depending on prior treatment history, cirrhosis status and baseline viral load.

"To date approximately 117,000 patients have been treated with Sovaldi and with the introduction of Harvoni - a single tablet regimen for the treatment of HCV-infected individuals which does not require either interferon or ribavirin - many more patients will have the potential to be cured of HCV infection," said John C. Martin, PhD, Gilead's Chairman and Chief Executive Officer.

Also, the Food and Drug Administration recently approved Gilead's drug Zydelig to treat leukemia and lymphoma.

Despite heavy criticism over its price tag, Sovaldi has been prescribed to more than 80,000 people, Gilead says. The total expense of a cure is much lower than that of a lifetime regimen. Hepatitis C can lead to cirrhosis, liver failure and liver cancer. The cost of a liver transplant alone is several hundred thousand dollars.

Nevertheless, some insurers and state Medicaid programs increasingly are restricting use of Sovaldi to those in advanced stages of the disease. And the Senate Finance Committee is looking into the pricing of Sovaldi.

Competitive challenges also loom for Gilead. Another new Hepatitis C drug, Olysio, from Growth Portfolio member Johnson & Johnson, had domestic sales of over $1 billion in the first half of the year. AbbVie is expected to gain regulatory approval for its hep C treatment, possibly followed by Merck and Bristol-Myers Squibb by 2016. And several companies are battling Gilead over patent rights tied to Sovaldi.

The most recent earnings report was strong enough to set off the stock's revival. Net income for the third quarter of 2014 was$2.73 billion, or$1.67per share, compared to$788.6 million or $0.47per share for the third quarter of 2013.

Because of Gilead's likely explosive growth, we consider the stock amazingly cheap, despite the concerns.We recommend that you buy up to 112.

Tom Scarlett is an investment analyst with Investing Daily.


It's Not YOUR Fault You Lose Money in the Stock Market

Plenty of investors have lost money in the stock market. In fact, it even happens to the best investors. So how do they get ahead then? Simple. They win more than they lose. And when they lose, they don't stubbornly hold on and lose it all waiting for the "dog" to turn around. But that's easier said than done. In fact, scientific studies have proven you're wired to lose… so it's not really your fault! Sadly, that doesn't change the result, though.

The good news is, I've spent the past 26 years perfecting a stock-picking system that's designed specifically to overcome the things that cause you to lose money. The first time I tested it out, I made a staggering profit of $127,344 on a single trade. And today I'm releasing it to the public.

You can get access to it when you click here.

Crude Delivers Another Shock

Ari Charney

On Wednesday, the normally cautious Bank of Canada did something that shocked the world, or at least the economists, traders and investors who closely monitor the central bank.

The drowsy institution, which had held its benchmark overnight rate at 1% since late 2010, the longest such pause in its history, announced that it would be cutting the rate by a quarter point, to 0.75%.

The bank characterized this latest move as insurance against the risks of falling inflation and possible financial instability. And that suggests this isn't the beginning of a new easing cycle, so much as a temporary measure to bolster the country's economy until growth reaccelerates.

Longtime readers will recall that back in the heady days of 2012, the Bank of Canada (BoC) was one of the first central banks in the developed world to take a hawkish stance toward monetary policy as the country's economy appeared to have shaken off the lingering effects of the Global Financial Crisis.

But Canada doesn't operate in a vacuum. Exports account for about 30% of the country's gross domestic product (GDP), and each year roughly three-quarters of those exports are absorbed by the U.S.

As the nascent U.S. recovery continued to drag on at levels that were downright anemic, at least until recently, while Canada's own economy decelerated, the bank was forced to abandon its upward bias.

However, the BoC was caught in a delicate balancing act between trying to prime Canada's economy, while not helping further inflate the country's housing bubble.

The fear was that a rate cut could spur further borrowing by the country's debt-burdened consumers--Statistics Canada recently reported that the ratio of household debt to disposable income hit a record high of 162.6% during the third quarter--while a rate increase could choke off emerging growth in other areas of the economy.

But crude oil's collapse finally altered the calculus. In its latest policy announcement, the BoC observed that the sharp drop in oil prices "will be negative for growth and underlying inflation in Canada."

Prior to crude's swoon, the central bank had forecast GDP would grow by an average of 2.4% in 2015 and 2.3% in 2016. But with the price of North American benchmark West Texas Intermediate crude oil having plunged nearly 57% from its trailing-year high, the BoC now sees growth coming in at 2.1% this year.

The bank forecasts markedly weak growth for the first half of the year, with GDP rising by an average of just 1.5%, before reaccelerating in the second half, particularly during the fourth quarter.

Among the bank's concerns is a serious drop in business investment in the energy sector, which we've already seen as a number of exploration and production companies have announced dramatic cuts to their capital budgets, while weaker terms of trade "will have an adverse impact on incomes and wealth, reducing domestic demand growth."

Although the resource space accounted for 8.1% of GDP in 2013, according to Statistics Canada, the sector is estimated to have been responsible for as much as 35% of private non-residential investment.

The BoC says falling energy sector investment will pare growth by a tenth of a percentage point, in contrast to prior forecasts that it would add four-tenths of a point to GDP this year. According to the Canadian Association of Petroleum Producers, energy sector spending is expected to decline by 33% this year, to CAD46 billion.

So energy's contribution to GDP doesn't fully reflect how the money it generates and borrows flows through the country's economy.

The good news is that the bank is more optimistic about the medium term, as evidenced by its projections for the second half of the year, though it acknowledges that its rosier outlook for that period is clouded by considerable uncertainty.

"Outside the energy sector, we are beginning to see the anticipated sequence of increased foreign demand, stronger exports, improved business confidence and investment, and employment growth," the central bank observed. Those are the top items on the BoC's wish list as it awaits the economy's eventual transition away from its dependence on overextended consumers.

But while there are indeed signs that this long-anticipated rotation has begun, the question is how quickly it will take to be fully realized.

Lower interest rates will certainly be helpful in aiding this transition. Meanwhile, a rapidly rebounding U.S. economy--the consensus forecast is for U.S. GDP to grow by a relatively robust 3.2% this year--should also provide a boost.

A lower exchange rate should help kick-start Canada's export economy as it makes the country's goods more attractive to consumers in other countries, especially the U.S.

The Canadian dollar has fallen sharply since mid-2014, as a result of two key factors.

First, the U.S. Federal Reserve became more hawkish about its own monetary policy by concluding its extraordinary stimulus with an eye toward its first short-term rate hike since late 2006. Then, of course, crude's sudden collapse further undercut the currency.

And with the BoC's latest move providing additional confirmation that the two central banks are heading in opposite directions in terms of monetary policy, the loonie will likely head even lower.

In fact, the exchange rate dropped by 2 cents following the BoC's announcement, which is a sizable swing in the world of currency trading. The loonie currently trades near USD0.806, its lowest level since the Great Recession.

Finally, lower prices at the gas pump will help give both U.S. and Canadian consumers additional purchasing power.

In contrast to the BoC's conservative projection, private-sector economists are more sanguine about the economy's prospects. According to Bloomberg, the consensus forecast among institutional economists is for Canada's GDP to grow by 2.4% this year, just shy of full capacity.

This article originally appeared in the Maple Leaf Memo column. Never miss an issue. Sign up to receive Maple Leaf Memo by email.


I've Found a Place Where Stocks Are on Sale!

Fourteen time zones from Manhattan, a 1,640-foot stretch of road is home to what will soon become the next Wall Street. A billion new middle-class consumers are set to unleash $30 trillion of economic change upon the world… much of which will hit this remote nation's shores in the coming years. Best, thanks to the U.S. dollar trouncing every other currency, you can buy stocks there for 14% off!

I've found five companies poised to exploit this wave and hand early investors triple-digit gains in the next 12 months.

Interested? Click here to get their names.

Investing in America's Renewal

Richard Stavros

Yet another reminder of the sad state of affairs of the nation's infrastructure: The collapse Monday of a section of the Interstate 75 bridge in Cincinnati that killed one construction worker.

Though crumbling roads, pipes and power grids is a global problem, the U.S. is the best place to invest in infrastructure. This according to two men who should know: Karl Kuchel, chief operating officer, Macquarie Infrastructure Partners, and Mark Weisdorf, founder of Weisdorf Associates and former CEO of J.P. Morgan Infrastructure Investments Group.

These two top bankers laid out the case for the U.S. as the best place for infrastructure investment in a webinar hosted by Privcap Media, which serves private capital investors.

Readers of Global Income Edge know one of our top long-term income investment themes is profits from the huge, rising demand for income-producing infrastructure investments.

There's a trillion dollars needed for infrastructure investment in the U.S. over the next seven to 10 years, and $400 billion alone will go to regulated utilities, where a large portion will be used for replacing aging coal plants with natural gas power plants, and adding renewable energy sources such as solar and wind. The American Society of Civil Engineers grades the country's infrastructure a D+.

The need for infrastructure investment has become more pressing in recent years. Weisdorf explained that though he has been speaking to investors around the world about infrastructure for 15 years, the problem has become particularly acute because investment in it stopped as a result of the global financial crisis. I've known firsthand about aging infrastructure, having been an adviser on multi-billion dollar energy projects.

The bankers said private investment in infrastructure is surging because many governments don't have the means to pay for it, and are turning to public/private arrangements with investors. Weisdorf said that over the last two years demand by private investors has increased dramatically because those investors are interested in the income such arrangements generate.

And infrastructure investments have two more things going for them. First, the pool of high-yield investments is shrinking worldwide. And second, infrastructure investments tend not to be linked to the fortunes of the stock and bond markets. This independence means adding them to your portfolio will decrease volatility. These investments are stable because they're guaranteed by the "public" half of the public/private partnerships, just as muni bonds are backed by the faith and credit of the municipality that issues them.

Weisdorf said stable infrastructure investments have become more attractive to investors given swings in stock markets and low rates on government debt around the world.

Macquarie

Source: Macquarie

The Case for America

Kuchel noted that U.S. infrastructure is attracting not only U.S. investors, but global investors as well.

The U.S. should have many public/private infrastructure investment opportunities given many state governments are facing sizable deficits with no money to put big down payments on infrastructure investments.

That's why Global Income Edge has developed portfolios that have stakes in the top energy utilities, telecoms and other infrastructure companies around the world.


A Critical Resource Shortage

Every year frackers use 140 billion gallons of a surprising resource. And now supplies have reached critically low levels. Drillers are in an all-out rush to lock up supplies from wherever – and whomever – they can get it from.

I've found two surprising companies that have a stranglehold on vital supplies of this material. Both are happily selling at ridiculous premiums.

To discover how this situation could turn every $1,000 you invest into $11,109…

just click here.

You are receiving this email at benjamart.ss.stock@blogger.com as part of your subscription to Investing Daily's Stocks To Watch,
published by Investing Daily. To ensure delivery directly to your inbox, please add
postoffice@investingdaily.com to your address book today.

Email Preferences | About Us | Premium Services | Contact Us | Privacy Policy

Copyright 2015 Investing Daily. All rights reserved.
Investing Daily, a division of Capitol Information Group, Inc.

7600A Leesburg Pike
West Building, Suite 300
Falls Church, VA 22043-2004
U.S.A.

0 comments:

Post a Comment

Subscribe to RSS Feed Follow me on Twitter!